Insider transactions

EDGAR

Decoy Therapeutics Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
2 transactions, 27 shares
Sum of shares × price per share: 17.2719

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–12 of 12

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-08-31 Filed 2026-09-02Burleson Tess Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,0000—2,002Direct (D) No
F1, F2
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
  • F2 Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Open filing 0001769749-26-000003 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02PIERCE FREDERICK II Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)33,4550—34,844Direct (D) No
F1, F2
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.
  • F2 Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.
Open filing 0001229055-26-000002 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02Lammers Paul Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,0000—2,001Direct (D) No
F1, F2
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
  • F2 Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Open filing 0001457289-26-000003 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02Rosenblum Mark J Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)9,6820—11,363Direct (D) No
F1, F2
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.
  • F2 Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Open filing 0001329154-26-000003 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02Lieber Jonathan I Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,0000—2,002Direct (D) No
F1, F2
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
  • F2 Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Open filing 0001193125-26-380584 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02Gauthier Patricia G. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,0000—2,000Direct (D) No
F1
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
Open filing 0002148287-26-000002 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02HANISH ARNOLD C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,0000—3,418Direct (D) No
F1, F2
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
  • F2 Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.
Open filing 0001233253-26-000006 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02Marschel Peter Klaus Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,9000—3,900Direct (D) No
F1
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.
Open filing 0002079859-26-000002 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02Hibner Barbara Louise Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)4,2160—4,216Direct (D) No
F1
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.
Open filing 0002079512-26-000002 Read from the filing’s XML Dispute this row
2026-08-31 Filed 2026-09-02McVicar William K. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)3,0000—3,002Direct (D) No
F1, F2
  • F1 Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, 100 percent will vest on August 30, 2027.
  • F2 Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Open filing 0001634368-26-000003 Read from the filing’s XML Dispute this row
2025-12-30 Filed 2026-01-02HANISH ARNOLD C Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)150.6397
9.5955

Derived: shares × price per share. Exact value 9.5955.

5,000Indirect (I) By Arnold C. Hanish TrustNo— Open filing 0001615219-26-000004 Read from the filing’s XML Dispute this row
2025-12-30 Filed 2026-01-02HANISH ARNOLD C Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)120.6397
7.6764

Derived: shares × price per share. Exact value 7.6764.

0Direct (D) No— Open filing 0001615219-26-000004 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–6 of 6

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
COMMONWEALTH EQUITY SERVICES, LLC Partly reported under another manager32,000 SH63,040 dollarsNot in the prior quarter’s filings read Open filing 0000312272-26-000024 Filed 2026-11-02 Dispute this row
UBS Group AG Partly reported under another manager4,525 SH8,914 dollarsHigher by 4,500 Prior quarter: 25Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 4,034 SH7,947 dollarsUnchanged Prior quarter: 4,034Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager3,735 SH7,358 dollarsHigher by 3,479 Prior quarter: 256Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
SBI Securities Co., Ltd. 111 SH219 dollarsNot in the prior quarter’s filings read Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager80 SH170 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Caitong International Asset Management Co., Ltd 2 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
CVI Investments, Inc. Common Stock, $0.0001 par value per share9.972,71709/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001649553-26-000138 Dispute this row
Heights Capital Management, Inc. Common Stock, $0.0001 par value per share9.972,71709/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001649553-26-000138 Dispute this row
Armistice Capital, LLC Common Stock, par value $0.0001 per share9.9965,503.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001172661-26-003569 Dispute this row
Steven Boyd Common Stock, par value $0.0001 per share9.9965,503.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001172661-26-003569 Dispute this row
CVI Investments, Inc. Common Stock, $0.0001 par value per share9.9708,56512/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001649553-26-000025 Dispute this row
Heights Capital Management, Inc. Common Stock, $0.0001 par value per share9.9708,56512/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001649553-26-000025 Dispute this row
Mitchell P. Kopin Common Stock, par value $0.0001 per share4.99187,295.0011/12/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001213900-25-111043 Dispute this row
Daniel B. Asher Common Stock, par value $0.0001 per share4.99187,295.0011/12/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001213900-25-111043 Dispute this row
Intracoastal Capital LLC Common Stock, par value $0.0001 per share4.99187,295.0011/12/2025 Filed 2025-11-14SCHEDULE 13GOpen filing 0001213900-25-111043 Dispute this row
CVI Investments, Inc. Common Stock, $0.0001 par value per share9.9362,49911/11/2025 Filed 2025-11-18SCHEDULE 13GOpen filing 0001649553-25-000209 Dispute this row
Heights Capital Management, Inc. Common Stock, $0.0001 par value per share9.9362,49911/11/2025 Filed 2025-11-18SCHEDULE 13GOpen filing 0001649553-25-000209 Dispute this row
C/M Capital Master Fund, LP Common Stock, par value $0.0001 per share00.0010/07/2025 Filed 2025-10-14SCHEDULE 13GOpen filing 0000902664-25-004399 Dispute this row
C/M CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share00.0010/07/2025 Filed 2025-10-14SCHEDULE 13GOpen filing 0000902664-25-004399 Dispute this row
Thomas Walsh Common Stock, par value $0.0001 per share00.0010/07/2025 Filed 2025-10-14SCHEDULE 13GOpen filing 0000902664-25-004399 Dispute this row
Jonathan Juchno Common Stock, par value $0.0001 per share00.0010/07/2025 Filed 2025-10-14SCHEDULE 13GOpen filing 0000902664-25-004399 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,687,210 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015103,592
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to Decoy Therapeutics Inc.